Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FluoGuide Announces Positive Topline Results from Phase IIa Trial of FG001 in Lung Cancer
FluoGuide, a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positive […]
Genprex Receives Approval to Advance Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with Non-Small Cell Lung Cancer
Scorpion Therapeutics, a pioneering oncology company redefining the frontier of precision medicine through its Precision […]
Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning […]
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
VITRAC Therapeutics initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with […]
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo has announced that the European Medicines Agency (EMA) has validated the Type II […]
XtalPi and EDDC Collaborate in AI-empowered Drug Discovery Program for Non-Small Cell Lung Cancer
XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, has announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more